Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting
Company Anticipates Biosimilar Application to be Submitted By End of Calendar Year 2022
PHILADELPHIA, June 11, 2020 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke wi... Biopharmaceuticals, Generics, FDA Lannett, biosimilar, insulin, glargine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news